PAR

4.55%

23.0¢ paradigm biopharmaceuticals limited..

What a post!Just on that failed Phase 2a trial for Lorecivivint,...

First 66 Last

Share
Profile

Follow
Dungiven

1,708 Posts.

1864

12/11/21

15:02

Post #: 57533145
Share

Originally posted by Zenox: ↑

There are a lot of issues with LOR which make it difficult to ascertain whether it will be considered favourably by the FDA, so I wouldn't consider it competition just yet. Here are some of the concerns the FDA are likely to have:

1. It was a post-hoc analysis from a failed study.

2. Background analgesia makes it difficult to determine the extent of the effect due to LOR.

3. Dropouts were excluded from analysis. Dropouts are most likely non-responders. FDA will perform sensitivity analysis and will treat dropouts as non-responders, which will negatively impact on the overall results.

4. The type of analysis performed was responder analysis, which you have to be cautious of when interpreting these results. For responder analysis you need to be able to identify who will respond to your treatment beforehand, which they are unable to just yet.

For the responder analysis, responders were compared groupwise between the LOR and PBO groups and logistic regression was performed on the full analysis set with non-responder imputation. These are not stringent forms of analyses, particularly imputation.

Article: Comparisons against baseline within randomised groups are often used and can be highly misleading
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286439/

5. The dosage results are inconsistent and not dose dependent. Why does 0.07 LOR dose 'work', but not 0.15? The overall number of participants in this group were small ~ 60-70 participants in each group.

6. Type 1 error control was not employed in the post hoc response analysis, so you can't trust the p values.

7. There are no objective measures supporting their findings i.e. no MRI scans.

The best case scenario for LOR is it will be considered as part of the treatment algorithm that will also include iPPS, but they still have a mountain to climb.

Expand

What a post!

Just on that failed Phase 2a trial for Lorecivivint, the primary endpoint was pain score and no dose showed statistical significance against placebo. The researchers, as is their wont, looked for silver linings - but Dr David Felson was not having any of it...

Bang!

https://www.medpagetoday.com/rheumatology/arthritis/86677

PAR Price at posting: $2.25 Sentiment: Buy Disclosure: Held
14 Upvote

4 Great analysis

Reply

Top Stories

WNX

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Emerald & Azure score Digger & Dealer awards

SVL

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

ARD

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

M2R

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

VTM

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Bitcoin: Current State of Play & Where to Next | Swyftx

EQR

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

IMD

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

There are more pages in this discussion • 2 more messages in this thread...

First 66 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 23.0¢		Change 0.010(4.55%)		Mkt cap ! $80.45M

Open	High	Low	Value	Volume
22.8¢	23.3¢	22.5¢	$46.92K	203.9K

Buyers (Bids)

No.	Vol.	Price($)
1	337	23.0¢

Sellers (Offers)

Price($)	Vol.	No.
23.5¢	138166	5

View Market Depth

No.	Vol.	Price($)
1	337	0.230
4	84610	0.225
14	174871	0.220
6	73458	0.215
5	131050	0.210

Price($)	Vol.	No.
0.235	138166	5
0.250	15000	1
0.260	26050	3
0.270	13000	2
0.275	10000	1

Last trade - 16.10pm 16/08/2024 (20 minute delay)

PAR (ASX) Chart

What a post!Just on that failed Phase 2a trial for Lorecivivint,...

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Emerald & Azure score Digger & Dealer awards

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Bitcoin: Current State of Play & Where to Next | Swyftx

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

What a post!Just on that failed Phase 2a trial for Lorecivivint,...

Top Stories

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Emerald & Azure score Digger & Dealer awards

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Bitcoin: Current State of Play & Where to Next | Swyftx

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News